ATYR → $22.00 by Jul 9, 2026.

aTyr Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $22.00 price target. Soumit Roy has given his Buy rating due to a combination of factors including the promising outlook for aTyr Pharma’s drug, efzofitimod, in the treatment of pulmonary sarcoidosis. The company is set to release Phase 3 topline data in the third quarter of 2025, and statistical analyses suggest …